AFFIMED
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
AFFIMED
Industry:
Biotechnology Clinical Trials Health Care Medical Therapeutics
Founded:
2000-01-01
Address:
Heidelberg, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.affimed.com
Total Employee:
51+
Status:
Active
Contact:
+49 (0)6221-6743-60
Total Funding:
534.03 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon WordPress Font Awesome Mobile Non Scaleable Content HSTS Organization Schema Sitelinks Search Box Yoast WordPress SEO Plugin
Similar Organizations
Agenus
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
bit.bio
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Castor
Castor offers a cloud-based clinical data platform that simplifies and streamlines clinical trials processes.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
UniQure
uniQure is focused on the research and early development of human gene-based therapies.
Verona Pharma
Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Employees Featured
Arndt Schottelius Chief Scientific Officer (CSO) @ Affimed
Chief Scientific Officer (CSO)
Melvyn Little Founder @ Affimed
Founder
Adi Hoess CEO @ Affimed
CEO
2011-09-01
Angus Smith CFO @ Affimed
CFO
Wolfgang Fischer Chief Operating Officer @ Affimed
Chief Operating Officer
2017-09-01
Denise Mueller Chief Business Officer @ Affimed
Chief Business Officer
Florian Fischer CFO @ Affimed
CFO
2005-03-01
Andreas Harstrick Chief Medical Officer (CMO) @ Affimed
Chief Medical Officer (CMO)
Leila Alland Chief Medical Officer @ Affimed
Chief Medical Officer
2018-03-01
Founder
Stock Details
Investors List
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Affimed
Roche
Roche investment in Post-IPO Equity - Affimed
Aeris Capital
Aeris Capital investment in Post-IPO Equity - Affimed
German Federal Ministry of Education and Research
German Federal Ministry of Education and Research investment in Grant - Affimed
Perceptive Advisors
Perceptive Advisors investment in Debt Financing - Affimed
BioMedPartners
BioMedPartners investment in Series E - Affimed
OrbiMed
OrbiMed investment in Series E - Affimed
Novo Holdings
Novo Holdings investment in Series E - Affimed
Aeris Capital
Aeris Capital investment in Series E - Affimed
EQT Life Sciences
EQT Life Sciences investment in Series E - Affimed
Official Site Inspections
http://www.affimed.com Semrush global rank: 3.3 M Semrush visits lastest month: 4.28 K
- Host name: 217-160-0-75.elastic-ssl.ui-r.com
- IP address: 217.160.0.75
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
Affimed.com lookup results from whois.ionos.com server:
- Domain created: 4th-Mar-2000
- Domain updated: 5th-Mar-2025
- Domain expires: 4th-Mar-2026 0 Years, 325 Days left
- Website age: 25 Years, 39 Days
- Registrar Domain ID: 21341246_DOMAIN_COM-VRSN
- Registrar Url: http://www.ionos.com
- Registrar WHOIS Server: whois.ionos.com
- Registrar Abuse Contact Email: abuse@ionos.com
- Registrar Abuse Contact Phone: +1.6105601459
- Name server:
- NS1108.UI-DNS.BIZ
- NS1108.UI-DNS.COM
- NS1108.UI-DNS.DE
- NS1108.UI-DNS.ORG
More informations about "Affimed"
Affimed Announces Leadership Change and Organizational …
Jan 8, 2024 Go forward organization will focus on advancing clinical programs; Company confirms guidance on data readouts for AFM24-102 and LuminICE-203 in H1 2024; …See details»
Corporate Governance - Affimed
Affimed Announces Leadership Change and Organizational …
Jan 8, 2024 Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount by up to 50%, extending cash runway into H2 2025Go forward organization will focus on …See details»
Affimed - Crunchbase Company Profile & Funding
Organization. Affimed . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of …See details»
Affimed N.V. (LON: 0HL9) Company Profile & Overview - Stock …
1 day ago Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s …See details»
Affimed - The Org
Breakthrough in cancer therapies: directing the immune system to eliminate tumor cells.See details»
Affimed Information - RocketReach
Affimed has three active clinical programs focused on solid tumors and blood cancers. The lead candidate Acimtamig (AFM13) is in development for patients with CD30-positive lymphomas. …See details»
About us - Affimed
Affimed fosters and continues to seek partnerships that align with the company’s overall corporate strategy. Working together, we aim to advance our clinical programs and enhance the development of our internal pipeline in an effort to …See details»
Affimed Company Profile 2024: Stock Performance & Earnings
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are …See details»
Affimed Announces Leadership Change and Organizational …
Jan 8, 2024 Affimed N.V. Dr. Adi Hoess to step down as CEO and Management Board Member. Dr. Andreas Harstrick appointed Interim CEO. Strategic restructuring reducing headcount by …See details»
Affimed GmbH - Drug pipelines, Patents, Clinical trials - Synapse
Explore Affimed GmbH with its drug pipeline, therapeutic area, technology platform, 13 clinical trials, 155 news, and 16 literature, Disease Domain:Neoplasms, Hemic and Lymphatic …See details»
Affimed to Report Third Quarter 2024 Financial Results
MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability …See details»
Affimed - Gilde Healthcare
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the …See details»
Affimed Announces Leadership Change and Organizational
Jan 8, 2024 Affimed also announced today a restructuring initiative aimed at transforming the Company into a focused clinical organization, positioned to successfully advance its clinical …See details»
Affimed Announces Acimtamig and AlloNK® Combination …
Dec 5, 2024 Affimed N.V. Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed …See details»
Innately Affimed - Affimed
That define Affimed and drive our unrelenting spirit in the fight against cancer. Culture Explore the values that shape our culture, bring us together, and keep us on the path toward achieving our …See details»
Affimed Revenue - Stock Analysis
1 day ago Affimed had revenue of 164.00K EUR in the quarter ending September 29, 2024, a decrease of -91.62%. This brings the company's revenue in the last twelve months to 5.64M, …See details»
Affimed (AFMD) Earnings Date and Reports 2025 - MarketBeat
Dec 27, 2024 Get the Latest News and Ratings for AFMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Affimed and its competitors …See details»
News and Events - Affimed
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma. …See details»
Affimed Announces Positive Results Demonstrating Safety and …
Dec 8, 2024 The combination of acimtamig with AlloNK ® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, …See details»